Viabrane Inc.
Viabrane is developing a proprietary intracellular delivery platform that enables therapeutic proteins, including antibodies, to reach previously inaccessible cytosolic disease targets.
TreatmentMVPHungary
See the full profile
The pitch deck, traction, financials and competitive detail are visible to approved investors, mentors and corporates. Log in or join EndCancer.Life to request access.
Company info
- Countries of Operation
- Hungary
- Founding Year
- 2025
- Number of Employees
- 6–10
Company overview
- Full Description
- Viabrane is a biotechnology company developing a proprietary intracellular delivery platform for therapeutic proteins, enabling antibodies and other biologics to access cytosolic disease targets that are otherwise inaccessible to conventional biologics.
- Areas of focus
- Oncology / Enzime Replacement Therapy / Rare diesases / Intracellular access
- Problem Statement
- Many disease-driving proteins are located inside cells, but therapeutic proteins such as antibodies generally cannot cross the plasma membrane or escape intracellular vesicles in functional form. This prevents biologics from addressing a large class of high-value intracellular targets, including oncogenic drivers such as KRAS. Existing delivery approaches often face inefficient uptake, endosomal trapping, cargo degradation, toxicity, limited protein compatibility or complex formulation. The unmet need is a modular, safe and efficient technology that can deliver intact therapeutic proteins into the cytosol at pharmacologically relevant concentrations and can be integrated into drug-development workflows.
- Solution Overview
- Viabrane addresses this bottleneck with a proprietary peptide-based intracellular delivery platform designed to transport therapeutic proteins into the cytosol in functional form. In vitro studies show efficient uptake at low extracellular concentrations and cytosolic enrichment of approximately 500–1,000 nM from ≤100 nM exposure. The platform is non-viral, modular and compatible with different protein cargos, including antibodies, with options for recombinant fusion. Compared with approaches optimized for nucleic acids, small-molecule payloads or non-specific cationic uptake, Viabrane is differentiated by validated protein-cargo delivery, high cytosolic enrichment, low-dose activity and rapid cargo screening. This could unlock new biologic therapies against previously inaccessible intracellular targets.
Interested in this innovator?
Send a short message. We’ll pass it to Viabrane Inc. with your name and email, so they can reply.
Request an introduction
Create an account or log in to send this request. Already a member? Log in
Introductions to innovators are open to innovators, investors, mentors and corporates.